Our Mission
We bring medicines that matter to patients and healthcare providers.
Our Vision
We strive for excellence in all we do to improve the quality of life for patients around the world.
Our business model is based on three strategic pillars
DIVERSIFIED PRODUCT PORTFOLIO
We are able to adapt to local demands and patient needs in each market.
- Diversified portfolio of prescription medicines, OTC drugs and branded generics
- Flexibility to adapt the portfolio to local market needs
- Leading product is panto-prazole (Gastroenterology)
- Key growth drivers are Respiratory and Specialty products as well as Regional and Local Rx
STRONG POSITION IN EMERGING MARKETS
We are continuing to expand our already strong presence in fast-growing markets.
- 2010: 39% of net turnover from emerging markets (estimated for 2015: ~60%)
- Nycomed’s biggest markets are Russia/CIS and Brazil
- New affiliates in 2010 in Asia, Latin America, Turkey and the Middle East
- Affiliates in >70 countries
- European markets remain a solid backbone and regulatory point of reference
PARTNERSHIP APPROACH
We make the best use of external resources and focus on what we do best.
- R&D pipeline growth mainly driven by externally acquired compounds
- Local and global portfolio supplemented by in-licensing and acquisitions
- Commercial capabilities strengthened by partners such as Merck & Co.
- Geographical reach extended by partners such as Forest Laboratories